First line therapy: have we made any improvement?

被引：5
作者：
Bookman, Michael A. [1 ]
机构：
[1] Univ Arizona, Arizona Canc Ctr, Tucson, AZ 85721 USA
来源：
EUROPEAN JOURNAL OF CANCER | 2011年 / 47卷
关键词：
D O I：
10.1016/S0959-8049(11)70153-8
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
[No abstract available]
引用
收藏
页码：S93 / S103
页数：11
相关论文
共 36 条
[1]   Intraperitoneal cisplatin plus intravenous cyclophosphamide versus intravenous cisplatin plus intravenous cyclophosphamide for stage III ovarian cancer [J].
Alberts, DS ;
Liu, PY ;
Hannigan, EV ;
OToole, R ;
Williams, SD ;
Young, JA ;
Franklin, EW ;
ClarkePearson, DL ;
Malviya, VK ;
DuBeshter, B ;
Adelson, MD ;
Hoskins, WJ .
NEW ENGLAND JOURNAL OF MEDICINE, 1996, 335 (26) :1950-1955
[2]  
[Anonymous], J CLIN ONCOL
[3]  
[Anonymous], 2010, Cancer Facts Figures 2010
[4]   Intraperitoneal cisplatin and paclitaxel in ovarian cancer [J].
Armstrong, DK ;
Bundy, B ;
Wenzel, L ;
Huang, HQ ;
Baergen, R ;
Lele, S ;
Copeland, LJ ;
Walker, JL ;
Burger, RA .
NEW ENGLAND JOURNAL OF MEDICINE, 2006, 354 (01) :34-43
[5]   Epidoxorubicin versus no treatment as consolidation therapy in advanced ovarian cancer: results from a phase II study [J].
Bolis, G ;
Danese, S ;
Tateo, S ;
Rabaiotti, E ;
D'Agostino, G ;
Merisio, C ;
Scarfone, G ;
Polverino, G ;
Parazzini, F .
INTERNATIONAL JOURNAL OF GYNECOLOGICAL CANCER, 2006, 16 :74-78
[6]   Paclitaxel/carboplatin versus topotecan/paclitaxel/carboplatin in patients with FIGO suboptimally resected stage III-IV epithelial ovarian cancer a multicenter, randomized study [J].
Bolis, Giorgio ;
Scarfone, Giovanna ;
Raspagliesi, Francesco ;
Mangili, Giorgia ;
Danese, Saverio ;
Scollo, Paolo ;
Lo Russo, Domenica ;
Villa, Antonella ;
Aimone, Paola Daniela ;
Scambia, Giovanni .
EUROPEAN JOURNAL OF CANCER, 2010, 46 (16) :2905-2912
[7]   Evaluation of New Platinum-Based Treatment Regimens in Advanced-Stage Ovarian Cancer: A Phase III Trial of the Gynecologic Cancer InterGroup [J].
Bookman, Michael A. ;
Brady, Mark F. ;
McGuire, William P. ;
Harper, Peter G. ;
Alberts, David S. ;
Friedlander, Michael ;
Colombo, Nicoletta ;
Fowler, Jeffrey M. ;
Argenta, Peter A. ;
De Geest, Koen ;
Mutch, David G. ;
Burger, Robert A. ;
Swart, Ann Marie ;
Trimble, Edward L. ;
Accario-Winslow, Chrisann ;
Roth, Lawrence M. .
JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (09) :1419-1425
[8]   Topotecan compared with no therapy after response to surgery and carboplatin/paclitaxel in patients with ovarian cancer: Multicenter Italian trials in ovarian cancer (MITO-1) randomized study [J].
De Placido, S ;
Scambia, G ;
Di Vagno, G ;
Naglieri, E ;
Lombardi, AV ;
Biamonte, R ;
Marinaccio, M ;
Carteni, G ;
Manzione, L ;
Febbraro, A ;
de Matteis, A ;
Gasparini, G ;
Valerio, MR ;
Danese, S ;
Perrone, F ;
Lauria, R ;
De Laurentiis, M ;
Greggi, S ;
Gallo, C ;
Pignata, S .
JOURNAL OF CLINICAL ONCOLOGY, 2004, 22 (13) :2635-2642
[9]   Addition of epirubicin as a third drug to carboplatin-paclitaxel in first-line treatment of advanced ovarian cancer: A prospectively randomized gynecologic cancer intergroup trial by the Arbeitsgemeinschaft Gynaekologische Onkologie Ovarian Cancer Study Group and the Groupe d'Investigateurs Nationaux pour l'Etude des Cancers Ovariens [J].
du Bois, A ;
Weber, B ;
Rochon, J ;
Meier, W ;
Goupil, A ;
Bricht, S ;
Barats, JC ;
Kuhn, W ;
Orfeuvre, H ;
Wagner, U ;
Richter, B ;
Lueck, HJ ;
Pfisterer, J ;
Costa, S ;
Schroeder, W ;
Kimmig, R ;
Pujade-Lauraine, E .
JOURNAL OF CLINICAL ONCOLOGY, 2006, 24 (07) :1127-1135
[10]   A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer [J].
du Bois, A ;
Lück, HJ ;
Meier, W ;
Adams, HP ;
Möbus, V ;
Costa, S ;
Bauknecht, T ;
Richter, B ;
Warm, M ;
Schröder, W ;
Olbricht, S ;
Nitz, U ;
Jackisch, C ;
Emons, G ;
Wagner, U ;
Kuhn, W ;
Pfisterer, J .
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE, 2003, 95 (17) :1320-1330
1234